Clinical Trials Logo

Von Willebrand Disease clinical trials

View clinical trials related to Von Willebrand Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01651468 Withdrawn - Menorrhagia Clinical Trials

The Effect of the Nutraceutical "Hemofix" on the Coagulation System

Start date: September 2016
Phase: N/A
Study type: Interventional

Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.

NCT ID: NCT00694785 Withdrawn - Clinical trials for Von Willebrand Disease

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

Start date: October 2008
Phase: Phase 2
Study type: Interventional

To evaluate the effect of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with Type2B von Willebrand Disease.

NCT ID: NCT00630448 Withdrawn - Clinical trials for Von Willebrand Disease

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

Start date: November 2008
Phase: N/A
Study type: Observational

Von Willebrand disease is an inherited bleeding disorder that impacts the blood's ability to clot properly. Von Willebrand disease is cause by the lack or not working substance in the blood known as Von Willebrand factor. Current therapy for Von Willebrand disease includes desmopressin acetate (DDAVP) and /or VWF/FVIII concentrates. Patients with severe Von Willebrand disease face a lifetime of weekly treatments and mounting medical bills. Gene therapy could help these patients improve their quality of life by providing the missing factors necessary for the blood's ability to clot properly. The gene transfer options being studied include naked DNA, viral gene transfer vectors encoding Von Willebrand factor transgenes, and ex vivo cell therapy. The latter involves transplantation of the patient's own cells modified with a corrected copy of the defective gene. Human blood outgrowth endothelial cells (BOEC) display all the properties needed for successful ex vivo cell therapy. We plan to obtain blood samples from normal research subjects and patients with Von Willebrand Disease in order to isolate blood outgrowth endothelial cells (BOEC) from peripheral blood, and develop a ex vivo gene therapy for Von Willebrand Disease.